What is the level of liabilities of Biomerieux this year?
Biomerieux has a debt balance of 1.51 B EUR this year.
Biomerieux Liabilities 2024
Biomerieux Liabilities
1.51 B EUR
Ticker
BIM.PA
ISIN
FR0013280286
WKN
A2DXZH
In 2024, Biomerieux's total liabilities amounted to 1.51 B EUR, a -4.76% difference from the 1.58 B EUR total liabilities in the previous year.
Biomerieux Aktienanalyse
What does Biomerieux do?
Biomerieux SA is a French company that operates in the field of in vitro diagnostics. The company was founded in 1963 by French biologist Alain Merieux and has since continued to grow. Today, Biomerieux employs around 12,000 people in over 150 countries worldwide and is listed on the Paris Stock Exchange. Biomerieux's business model is based on the development, production, and marketing of diagnostic products for various areas of medicine. This includes infectious diseases, cancer, and cardiovascular diseases. The company is divided into two main business segments: Clinical Diagnostics and Industrial Microbiology. Under the Clinical Diagnostics segment, Biomerieux offers a wide range of diagnostic products for infectious diseases, including molecular diagnostics, blood-based tests, and laboratory automation solutions. Some of the most well-known products include the VIDAS immunodiagnostic test, the FilmArray multiplex PCR test, and the VITEK automated system for microorganism identification. Under the Industrial Microbiology segment, Biomerieux is a leading provider of products for the microbiological analysis of food, beverages, and pharmaceutical products. The company offers a wide range of products for microbiological quality control, which help ensure the safety and quality of food and pharmaceutical products. These include the TEMPO system for assessing microorganism growth and the Bactalert blood culture system for rapid detection of bacteria in blood cultures. In addition to its main business segments, Biomerieux also offers specialty products for use in veterinary diagnostics and water analysis. The company works closely with clinical laboratories and health authorities to improve the diagnosis of infectious diseases and combat epidemics. Over the years, Biomerieux has built a strong research and development department focused on developing innovative diagnostic products. The company has also made a number of strategic acquisitions to expand its product portfolio and enter new markets. For example, in 2020, Biomerieux acquired Suzhou Hybiome Biomedical Engineering in China to strengthen its presence in the Chinese market. In summary, Biomerieux is a leading company in the field of in vitro diagnostics. Its wide range of products and global network make it an important partner for laboratories, hospitals, and the food and pharmaceutical industries. With its strong research and development department and strategic acquisitions, Biomerieux will continue to play a crucial role in the fight against infectious diseases and the improvement of patient care. Biomerieux ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Biomerieux's Liabilities
Biomerieux's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Biomerieux's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Biomerieux's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Biomerieux's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Biomerieux’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Biomerieux stock
What were the liabilities of Biomerieux compared to the previous year?
The liabilities of Biomerieux have increased by -4.76% dropped compared to the previous year.
What are the consequences of high debt for investors of Biomerieux?
High liabilities can pose a risk for investors of Biomerieux, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Biomerieux?
Low liabilities mean that Biomerieux has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Biomerieux affect the company?
An increase in liabilities of Biomerieux can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Biomerieux affect the company?
A decrease in the liabilities of Biomerieux can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Biomerieux?
Some factors that can influence the liabilities of Biomerieux include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Biomerieux so important for investors?
The liabilities of Biomerieux are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Biomerieux take to modify the liabilities?
To change its liabilities, Biomerieux can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Biomerieux pay?
Over the past 12 months, Biomerieux paid a dividend of 0.85 EUR . This corresponds to a dividend yield of about 0.87 %. For the coming 12 months, Biomerieux is expected to pay a dividend of 0.94 EUR.
What is the dividend yield of Biomerieux?
The current dividend yield of Biomerieux is 0.87 %.
When does Biomerieux pay dividends?
Biomerieux pays a quarterly dividend. This is distributed in the months of July, July, July, July.
How secure is the dividend of Biomerieux?
Biomerieux paid dividends every year for the past 24 years.
What is the dividend of Biomerieux?
For the upcoming 12 months, dividends amounting to 0.94 EUR are expected. This corresponds to a dividend yield of 0.96 %.
In which sector is Biomerieux located?
Biomerieux is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biomerieux kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biomerieux from 6/11/2024 amounting to 0.85 EUR, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.
When did Biomerieux pay the last dividend?
The last dividend was paid out on 6/11/2024.
What was the dividend of Biomerieux in the year 2023?
In the year 2023, Biomerieux distributed 0.85 EUR as dividends.
In which currency does Biomerieux pay out the dividend?
The dividends of Biomerieux are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biomerieux stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Biomerieux
Our stock analysis for Biomerieux Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomerieux Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
